WALTHAM, Mass.--(BUSINESS WIRE)--May 5, 2006--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a leading developer of biopharmaceutical compounds designed to treat cancer and certain ophthalmologic diseases, today announced that the U.S. Patent Office issued a patent to OXiGENE for its lead clinical compound, Combretastatin A4P (CA4P). The patent entitled, "Methods for Modulating Tumor Growth and Metastasis" (U.S. Patent No. 7037906), provides broad coverage through 2021 for the use and administration of CA4P in combination with paclitaxel, one of the most widely used chemotherapeutic agents for oncology.
